According to data from a study released by the Government of Chile, on the effectiveness of the vaccine from the Chinese laboratory Sinovac prevents 67% of infections by COVID-19.
“This means that of 100 people who would have had COVID-19, there would only be 33 cases if we were all vaccinated,” Rafael Araos, advisor at the Ministry of Health, explained at a press conference.
The Coronavac vaccine, which is of the inoculated virus type and requires two doses, also prevents 80% of deaths, 85 of hospitalizations and 89% of admissions to intensive care units 14 days after being applied the second injection.
This is the first large study in the real population on this vaccine and not a clinical trial, which only measures the efficacy with volunteers and under specific conditions, for which about 10.5 million people were followed between the 2 of February and April 1.
“In a scenario of high epidemiological activity and in susceptible groups, the vaccine studied protects against symptomatic infection by SARS-CoV-2, as well as against the most serious forms of the disease,” said the expert.
Since no vaccine is 100% effective, he added, it is critical that we all get vaccinated.
Since the beginning of February, Chile has applied about 13 million vaccines (90% from Coronavac and the rest from Pfizer / BioNTech) and more than 7.6 million people have received at least one dose, of which 5.1 million have already completed the inoculation, representing 33.7% of the target population
Chile, which has committed more than 35 million doses from different laboratories and expects to achieve herd immunity in June, has authorized the administration of 4 vaccines to date: Pfizer / BioNTech, Coronavac, AstraZeneca and recently that of the Chinese laboratory CanSino.
Experts point out that the successful vaccination process could have played against Chile and led its 19 million inhabitants to an excess of confidence, to which is added fatigue after a year with restrictions and the circulation of new variants.
The Chilean authorities, however, did not specify if the vaccine protects against the Brazilian, British and South African variants, which are already present in the country, which has more than 1.1 million infected since March last year and about 24,800 deaths.